Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An analgesic derived from pyrazolone, inhibitor of prostaglandin synthesis by inhibiting cyclooxygenase.
Administered orally and rectally.
Since the last update date we have not found published data on its excretion in breastmilk.
Severe hemolytic anemia has been reported in a newborn whose mother was taking it (Frei 1985).
Since 1989, it has been withdrawn from sale in many countries for having caused medullary aplasia, Lyell's syndrome and other serious side effects (Onakpoya 2018).
It is marketed in multiple preparations that combine caffeine, codeine, atropine and anti-inflammatory drugs. In general, drug combinations are not recommended and even less so during breastfeeding.
Known alternatives which are safer during breastfeeding are preferred, especially during the neonatal period and in the case of prematurity.